Calypso Enters into Agreement to Be Acquired by Novartis

09-Jan-2024 - Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...

MorphoSys Completes Technology Transfer in Strategic Antibody Alliance

Full Installation of HuCAL Platform Triggers Double-Digit Million Euro Milestone Payment

01-Mar-2011 - MorphoSys AG announced that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland. The milestone arises in connection with an option in the ...

ImmunoGen, Inc. Announces Collaboration for Rights to Use ImmunoGen’s TAP Technology

13-Oct-2010 - ImmunoGen, Inc.announced that it has entered into a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis. Under this agreement, Novartis will pay a $45 million upfront fee to ImmunoGen ...

MorphoSys Announces Clinical Milestone from Strategic Alliance

Second Clinical Milestone in 2010

05-Jul-2010 - MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to ...

Ablynx achieves third milestone in drug discovery and development collaboration

19-Nov-2009 - Ablynx announced that it will receive an undisclosed milestone payment from Novartis. The payment has been triggered by successful delivery to Novartis of Nanobody® candidates which met specific criteria. This will be the third milestone payment that Ablynx has received from Novartis since the ...

Ablynx Receives a Second Milestone Payment From Nanobody Discovery and Development Alliance

07-Oct-2009 - Ablynx announced that it has received an undisclosed milestone payment from Novartis for an exclusive research license in one of the programmes that is a component of their ongoing Research and Development alliance. Novartis and Ablynx are collaborating to discover and develop therapeutic ...

Ablynx announces extension of Nanobody drug discovery and development alliance

12-Dec-2007 - Ablynx announced that its drug discovery and development alliance with Novartis has been extended for another year. Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody® based therapeutics against disease targets ...

Galapagos and ProStrakan receive additional milestone payment in antibody collaboration

28-Sep-2007 - Galapagos NV and ProStrakan Group plc announced the achievement of the third milestone under Galapagos' collaboration with Novartis in antibodies for bone-related diseases. Today's milestone triggers a payment of $1.5 million to Galapagos. Galapagos will pay $1,125,000 of this amount to ...

Crucell Announces STAR Technology Research License Agreement

18-Sep-2006 - Crucell N.V. announced that it has started an evaluation program with Novartis AG. The program will apply Crucell's STAR(TM) technology for the selection of biopharmaceuticals production cell lines and to adapt such procedures to specific parental cell lines. The program will be performed with ...

MorphoSys Announces Expansion of Collaboration with Novartis

27-Jun-2006 - MorphoSys AG announced an expansion of its existing therapeutic antibody collaboration with Novartis. The original collaboration agreement provided for a three-year term with an option for Novartis to extend. The collaboration will now go through May 2011. In light of the expanded collaboration, ...